Galixir
We have a team with solid background in both AI and pharmaceutical science. Our core team members come from MIT, Yale, Johns Hopkins, THU, PKU and other top universities, as well as leading pharma and tech companies.
Justin Qin
Strategy and Business Development VPGan&Lee Pharmaceuticals
晓婷 郑
BD高级经理GATTACO Inc.
GattaCo develops products that enable fast accurate evidence-based decision making to improve healthcare outcomes. We do this by solving the fundamental problems in sample purification, the most challenging component of the diagnostic testing workflow.
Our new Plasm™ Module is a revolutionary, patented, automatic plasma separation and metering module or insert used to provide high-purity, metered plasma to a rapid diagnostic testing platform, such as lateral flow, biosensor, or other Point of Care (POC) device, from finger-stick capillary blood. The initial version of the Plasm Module is optimized for antibody testing and will revolutionize POC diagnostics by improving:
- Sensitivity: Increased number of antibodies compared to the same volume of whole blood.
- Specificity Accuracy: High quality/purity sample with reduced background.
- Repeatability: Plasma is metered to +/- 5%. Quantitation: Precisely metered output, independent of hematocrit.
Michael McNeely
Pres/CEOGC Ventures America
Dr. Tony Sun
CVC ManagerGCV Life
Dr. Chirag Jain
AnalystGeneception Inc.
Geneception is an innovation-driven biopharmaceutical company focusing on gene and cell therapy medicines.
Dr. Amber Cai
CEOGenervon Biopharmaceuticals
There is a high unmet need for central nervous system (CNS) diseases in the growing aging population. Chronic inflammation is associated with a broad spectrum of neurodegenerative diseases related to aging. Genervon is bringing GM6, a new clinical-stage drug asset, to regulatory approval and commercialization in China for CNS diseases including Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Multiple Sclerosis (MS), and other neurodegenerative diseases. Most clinical trials for drugs developed through the traditional single-target drug approach have failed to treat the complex neurological disorders that involve multiple interrelated pathways.
GM6 is an innovative first-in-class regulator peptide drug in clinical stage. Genervon Biopharmaceuticals discovered an endogenous embryonic-stage regulator, Motoneuronotrophic Factor (MNTF), and developed from it the pleiotropic drug GM6. GM6 is neither an antibody nor a single-target agonist or antagonist. It is a multi-target regulator which simultaneously acts upon multiple extracellular receptors to modulate a series of signaling pathways mediating inflammation and pro-survival responses in both CNS and immune system. Genervon has validated GM6’s target engagement of multiple targets and druggability. GM6 has been de-risked for toxicity in animal studies and safety in three clinical trials. IND documents filed with the FDA can be used to support regulatory filing in China for clinical trials. Genervon is interested to partner through licensing or merger and acquisition. A complete CMC package is ready for technology transfer.